Biogen and UCB on Tuesday shared an expanded dataset for their Phase 3 lupus program, which they said two months ago ...

A phase 3 trial of Biogen (NASDAQ:BIIB) and UCB's (OTCPK:UCBJF)(OTCPK:UCBJY) dapirolizumab pegol for systemic lupus ...

After the unexpected success of their PHOENYCS GO study for dapirolizumab pegol in lupus earlier this fall, Biogen and UCB ...

(RTTNews) - UCB and Biogen Inc. (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, a Fc-free anti-CD40L drug candidate, showing significant clinical ...

UCB and Biogen (BIIB) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol, or DZP, a novel Fc-free anti-CD40L drug candidate, demonstrating significant ...

United Community Bank (NYSE: UCB) named Matthew Bruno as its new Miami-Dade County regional president on Nov. 19. The leader ...

The board of United Community Banks, Inc. ( NYSE:UCB ) has announced that it will pay a dividend of $0.24 per share ...

UCB has three products currently in phase III which are due to produce pivotal results in the next few years: brivaracetam for epilepsy, lupus treatment epratuzumab and romosozumab for osteoporosis.